Journal of Clinical Immunology and Allergy

Novel I-O Drug Discoveries Empowered by Humanized Animal Models

16^th EuroSciCon Conference on Immunology
March 11-12, 2019 | Amsterdam, Netherlands

Yi Yang

Biocytogen, China

Keynote: J Clin Immunol Allergy

DOI: 10.21767/2471-304X-C1-007

Abstract

In vivo efficacy evaluation has always been a rate-limiting step during therapeutic antibody discovery due to species specificity. Using geneediting technology, we have generated and functionally validated a series of single and double humanized mouse models for the I/O field such as B-hPD-1/hPD-L1, B-CTLA-4, B-hOX-40, B-hCD47/h-SIRPa and B-hCD3e. These models are very useful not only for single agent treatment, but also for combination therapy and bispecific antibody development.

Biography

Dr. Yi (Benny) Yang received his Ph.D. degree in immunology from University of Connecticut and completed his postdoctoral training in New York University at Dr. Dan R. Littman’s group. Dr. Yang was a tenure-track Assistant Professor at Medical University of South Carolina from 2014 to 2016 and joined Biocytogen in 2016. He studied the newly discovered immune regulation of Th17 cells and intestinal microbial immunity, and published a series of paper on Nature, Science and Cell.

E-mail: info@biocytogen.com